Research Paper Volume 11, Issue 23 pp 11202—11223

Figure 1. ciRs-6 is downregulated in bladder cancer, and its downregulation is associated with poor prognosis. (A) Divergent (◀▶) and convergent (▶◀) primers were designed for ciRs-6 (◀▶) and its linear form, SLC41A2 (▶◀), respectively. Agarose gel nucleic acid electrophoresis was used to detect both the cDNA and gDNA forms of ciRs-6 and SLC41A2. (B) RNase R treatment was used to evaluate the exonuclease resistance of ciRs-6. (C) The diagram schematically illustrates the circulation of ciRs-6. (D) qPCR was used to detect the expression of ciRs-6 in 45 paired bladder cancer tissues and adjacent normal tissues. (E) The expression of ciRs-6 in 58 bladder cancer tissues was evaluated by qPCR and analyzed for high/low grade and (F) T stages. (G) Relationship between overall survival and ciRs-6 level in bladder cancer patients was analyzed by Kaplan-Meier curves and log-rank tests. The median value of the ciRs-6 level was used as the cutoff. The results are displayed as the mean±SEM, *p<0.05, **p<0.01.